Future of Tick Disease Protection


Imagine not needing to remember to use tick control each month, just annually given by a veterinary professional in conjunction with a yearly check-up.

Here are three facts:

  • In the U.S. there are more ticks in more places than ever before, which means significantly more tick diseases in dogs (and in people).  And ticks (for various reasons) are a threat more months of the year in Northern climates and continue to be a concern year-round elsewhere.
  • Dogs rarely remember to use a preventative and believe it or not us humans often don’t remember either. The issue is referred to as compliance, occurring either because we forget or maybe in an effort to save money the monthly preventatives aren’t given each month.
  • Tick disease is underdiagnosed in dogs.

A recent Australian study published in Parasites & Vectors called, “Year-round efficacy of a single treatment of fluralaner injectable suspension (Bravecto QuantumTM) against repeated infestations with Ixodes holocyclus in dogs” demonstrates an annual injectable may be possible.

Ixodes holocyclus, commonly known as the Australian paralysis tick, is one of about 75 species in the Australian tick, which can cause paralysis by injecting neurotoxins into its host and can be fatal.

In the U.S., it’s another Ixodes tick, Ixodes scapularis is commonly known as the deer tick or black-legged tick, which transmits Lyme disease, the most common tick disease in the U.S.

In two recent studies,  a group of 20 clinically healthy dogs faced off against the menacing Ixodes. holocyclus ticks. The dogs were divided into two groups: one remained untreated, while the other received a single treatment of the injectable fluralaner suspension on Day zero. Ticks were infested at various intervals over the course of 13 months.

The results were impressive.  The untreated control dogs consistently maintained a tick infestation, with mean tick counts ranging from 16.2 to 23.5. In contrast, the efficacy of the fluralaner injectable suspension was exceptional, with a 100 percent success rate in one study and up to 95.7 percent in the other. The treatment was so effective that it ensured protection against ticks from as early as one-week post-treatment through a staggering 13 months, making 12 months of protection a possibility to think about.

Of course, similar studies will need to be replicated in the U.S. before being approved.